Rescheduling’s Fine Print: DEA Becomes Mandatory Middleman

WASHINGTON – As of today, medical cannabis is on Schedule III — but operators hoping rescheduling would mean less federal interference should read the fine print. Under the order signed Thursday by Acting Attorney General Todd Blanche, the Drug Enforcement Administration becomes a nominal owner of every licensed cannabis crop in America. In addition, the federal government will collect an as-yet-undisclosed administrative fee on each harvest it processes through a mandatory buy/sell-back mechanism. And the DEA gains discretionary authority to approve or revoke federal registrations on undefined “public-interest” grounds.

The feds aren’t stepping back. They’re stepping in — as a silent business partner whose cut hasn’t been named yet.

The legal controversy: why Blanche bypassed public comment

Blanche acted unilaterally under Section 811(d)(1) of the Controlled Substances Act (CSA), a treaty-compliance provision that allows the attorney general to issue a scheduling order without the scientific review, public comment period, or administrative hearing required under standard rulemaking procedures. The maneuver is written into the CSA but is legally contested: The U.S. Court of Appeals for the D.C. Circuit previously held that placing cannabis below Schedule II would fail to satisfy U.S. obligations under the 1961 Single Convention on Narcotic Drugs, and the DEA itself took that position as recently as 2016. What changed? A 2024 Office of Legal Counsel opinion concluded Schedule III can satisfy treaty obligations if accompanied by specific regulatory controls, and Blanche’s order relies on that interpretation.

Litigation challenging the action is widely expected.

The Single Convention loophole: mandatory DEA buy-backs explained

The regulatory controls are where the mechanism gets unusual. The Single Convention requires a government agency to serve as the exclusive purchaser of cannabis production. To satisfy that requirement, the Department of Justice plans to implement a buy/sell-back process that applies specifically to growers. Licensed cultivators must store crops in DEA-accessible facilities, establish a nominal price, sell to DEA, and immediately repurchase their crop at the same price plus a to-be-determined administrative fee.

Processors, distributors, and dispensaries face a separate but equally consequential set of new federal obligations, including DEA registration, biennial inventories, transaction recordkeeping, theft and loss reporting, and product labeling and security requirements.

Physician recommendations vs. formal prescriptions

For dispensaries, an additional tension looms unresolved: Schedule III substances under the CSA must be dispensed by prescription, but state medical marijuana programs operate on physician recommendations, not formal prescriptions. Blanche’s order does not address how, or whether, that distinction will be reconciled.

Notably, the Single Convention’s language includes a carveout exempting medicinal cannabis preparations from the exclusive-purchaser requirement, which would appear to cover processors and retailers. It also arguably calls into question whether even the grower mechanism is treaty-required under medical rescheduling.

Is 280E relief worth it? The new DEA administrative fee

Blanche’s rescheduling order eliminates the Internal Revenue Code Section 280E deduction disallowance that has subjected cannabis businesses to effective federal tax rates as high as 40 percent by barring them from claiming most ordinary business expenses. Blanche’s order also encourages Treasury Secretary Scott Bessent to consider retroactive 280E relief for prior tax years in which operators held valid state medical licenses.

But the administrative fee that replaces one federally imposed cost of doing business is, at this moment, an undisclosed number. Unlike 280E — brutal but uniform and predictable — the DEA fee has no cap, no floor, and no published formula. It will be set by DEA under a regulatory provision that does not yet exist in final form. The industry is trading a known burden for an unknown one controlled entirely by the agency that also approves and revokes federal registrations.

Multi-state operators serving both medical and adult-use markets face additional uncertainty: Because Blanche’s rescheduling applies only to state-licensed medical products, tax relief may apply only to the medical portions of their businesses until the broader process concludes.

Compliance lag: why Schedule III reclassification isn’t instant

The Schedule III reclassification takes effect April 23 for FDA-approved products and state-licensed medical operators. But immediate rescheduling is not the same as immediately operational. The compliance infrastructure — DEA registration process, crop storage requirements, buy/sell-back mechanics, and the fee structure itself — all require implementing regulations that have not been written. Operators are technically in Schedule III territory as of now, but the federal registration pathway that will make them compliant under Schedule III remains undefined.

The 280E relief is more immediately actionable. Blanche’s order indicates operators may stop applying 280E to medical operations right away without waiting for implementing rules, though retroactive relief still requires separate Treasury and IRS action.

What comes next

At the same time Blanche reclassified medical marijuana, DOJ terminated the Biden-era administrative hearing process, which had stalled amid litigation over alleged agency bias and improper communications with anti-rescheduling parties. A new expedited hearing will begin June 29 to consider moving all marijuana, including adult-use products, to Schedule III. That hearing will be a formal adversarial proceeding: testimony, exhibits, cross-examination, transcript. Even under an optimistic scenario, a final rule extending rescheduling to the full market is unlikely before early to mid-2027, and litigation could push that further.

For state-licensed operators seeking federal registration as manufacturers, distributors, or dispensers, DOJ indicated it will establish an expedited review process that leverages existing state licensing infrastructure. Blanche’s order acknowledged state regulatory systems have “demonstrated a sustained capacity to achieve the public-interest objectives that underlie the CSA’s registration framework.” What it does not specify is when that registration process will open, what it will cost, or who will decide when a public-interest concern is sufficient to deny or revoke a license.

Crucially, the compliance rulemaking — DEA registration, buy/sell-back mechanics, crop-storage requirements, and the administrative fee — is a separate regulatory track from the June 29 hearing, and no timeline has been published for that component of the process. It could proceed in parallel, or it could wait. DOJ hasn’t said.

The result is a three-speed federal cannabis landscape: rescheduling effective today, compliance pathway coming eventually, broader adult-use rescheduling potentially years away. Operators who spent years waiting for federal rescheduling are now rescheduled — and still waiting to find out what that actually means in practice.